• Home
  • Contact
  • Phone: (267) 971-7725
  • Join our Facebook Group
  • Subscribe to our RSS Feed
  • Search Site

Bioquark

  • BackgroundMission & Strategy
  • The OpportunityThe Health Care Gap
  • Our ProgramsBioquantines
    • BQ-A
    • BQ-A In-Vivo Studies
    • BQ-A Clinical Plans
    • Health, Wellness and Beauty Care
    • Articles / Shows / Press Releases / Publications
    • Future Bioquantine Programs
  • About UsOur History
    • Our Team
  • Contact UsGet in Touch

You are here: Bioquark / Market Opportunity

Market Opportunity

The majority of the $7 trillion spent annually on health care globally is focused on the treatment of patients that have diseases with either a cellular damage or degeneration component.

Unfortunately, the current therapeutic tools used to address these needs, including organ transplantation, traditional pharmaceuticals, and, more recently, stem cell therapies, fall very short of actual cures.

Corporate Presentation 2013

Organ transplantation is limited by a substantial and growing donor gap and the unavoidable host-versus-graft reaction.  Traditional pharmaceuticals, while capable of interfering and slowing down degenerative processes, can do little to reverse damage once it has occurred, and typically only target the late-appearing indications of dysfunctional tissue / organ systems, as opposed to the biological factors that cause these abnormalities. Even the evolving stem cell space is running into many technical, efficacy, and regulatory challenges which will substantially limit the potential of the market for these replacement therapies.

An alternative, cost-efficient approach is required that can simultaneously address regeneration and repair therapeutic indications, leverage existing pharmaceutical regulatory pathways, and avoid the many limitations of the healthcare industry’s current offerings.

Combinatorial biologics that are capable of directly modifying biological regulatory state, fulfill all of these criteria.

Bioquark Inc. is a life sciences company, developing proprietary combinatorial biologics for the regeneration and repair of human organs and tissues.

BQ-A

BQ-A represents the first in a class of tissue regulatory state modifiers, which interact with the control apparatus of the genome to affect disease cure. (read more)

BQ-A In-Vivo Studies

BQ-A has been administered by several methods including subcutaneously, intraperitoneally, intratumorally, and topically. (read more)

BQ-A Clinical Plans

Bioquark is focusing on generating human clinical data in multiple therapeutic indications of unmet medical need. (read more)
© Copyright - Bioquark
  • scroll to top
  • Join our Facebook Group
  • Subscribe to our RSS Feed